No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NNVC240621P2500
- 0.86
- 0.000.00%
15min DelayTrading Jun 18 12:14 ET
0.00High0.00Low
0.00Open0.86Pre Close0 Volume47 Open Interest2.50Strike Price0.00Turnover879.16%IV13.46%PremiumJun 21, 2024Expiry Date0.60Intrinsic Value100Multiplier1DDays to Expiry0.26Extrinsic Value100Contract SizeAmericanOptions Type-0.5690Delta0.3524Gamma2.71Leverage Ratio-0.1576Theta-0.0001Rho-1.54Eff Leverage0.0005Vega
Intraday
- 5D
- Daily
News
Express News | NanoViricides Inc: NV-387 Treatment Resulted in Significant Reduction in Mucus Load in Lungs
Express News | NanoViricides Inc: NV-387 Treatment Significantly Protected Lungs of Balb-C Mice Lethally Infected With Influenza a/H3N2 Virus
Express News | NanoViricides Inc: NV-387 Treatment Resulted in Significant Reduction in Lung Infiltration and Lung Cell Death
Express News | NanoViricides Inc: Ultra-Broad-Spectrum Antiviral NV-387, Clinical Phase II Stage Drug Candidate, Was Found Effective in Protecting Lungs From Damage
Express News | Nanoviricides Reports That The Ultra-broad-spectrum Antiviral NV-387, A Phase 2 Stage Drug Candidate, Was Found To Be Effective In Protecting Lungs From Damage In A Lethally Infected Influenza H3N2 Mouse Model
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs From Damage in Lethally Infected Animal Model
SHELTON, CT / ACCESSWIRE / June 20, 2024 / NanoViricides, Inc. (NYSE AmerIcan.:NNVC) (the "Company"), a clinical stage company and global leader in broad-spectrum antiviral nanomedicines, reports that
Comments
$Nanoviricides(NNVC.US$ Nanoviricides Reports That The Ultra-broad-spectrum Antiviral NV-387, A Phase 2 Stage Drug Candidate, Was Found To Be Effective In Protecting Lungs From Damage In A Lethally Infected Influenza H3N2 Mouse Model
2
2
$Nanoviricides(NNVC.US$ Yes a beautiful uptrend overall since mid/late April. But more, very encouraging data for NV-387! A statement said a few months ago with results and data from early testing, that this could be the biggest thing in medicine since antibiotics. Well that would be amazing yes for stock price! But what that could mean for disease treatment overall could be a game changer? The early data seems that its still on that path.🤞❤️![]()
1
4
$Nanoviricides(NNVC.US$
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides announced a significant advancement in its lead antiviral agent, NV-387. This drug, designed for broad-spectrum antiviral treatment, has shown prolonged blood concentration levels in non-human primate models, indicating the potential for infrequent dosing. NV-387's unique polymeric design helps sustain drug levels, making it effecti...
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides announced a significant advancement in its lead antiviral agent, NV-387. This drug, designed for broad-spectrum antiviral treatment, has shown prolonged blood concentration levels in non-human primate models, indicating the potential for infrequent dosing. NV-387's unique polymeric design helps sustain drug levels, making it effecti...
4
$Nanoviricides(NNVC.US$
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, a leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class antiviral agent targeting RSV, COVID-19, Influenza, and other viruses. NV-387 employs novel host-mimetic technology to remain effective despite viral mutations. It has outperformed existing drugs such as remdesivir, T...
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, a leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class antiviral agent targeting RSV, COVID-19, Influenza, and other viruses. NV-387 employs novel host-mimetic technology to remain effective despite viral mutations. It has outperformed existing drugs such as remdesivir, T...
$Nanoviricides(NNVC.US$
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wi...
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wi...
1
Read more
103216711 : is this a good stock for the long term?
TrytosaveabitOP 103216711: I don’t have enough DD done on it to answer that honestly! GL